Point-Of-Care Molecular Diagnostics Market Poised For Growth Through 2034, Driven By Rapid Testing Demand, Decentralized Care And Diagnostic Innovation
Dublin, Sept. 17, 2026 (GLOBE NEWSWIRE) -- "Point-of-Care Molecular Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.
Point-of-Care Molecular Diagnostics Market to Reach USD 14.80 Billion by 2034
The global point-of-care molecular diagnostics market is estimated at USD 6.20 billion in 2025 and is projected to reach USD 14.80 billion by 2034, expanding at a compound annual growth rate of 10.2% from 2026 to 2034. Market growth is being driven by the rising burden of infectious diseases, increasing demand for near-patient testing, broader availability of CLIA-waived syndromic panels, and the emergence of over-the-counter molecular diagnostic products.
Point-of-care molecular diagnostic platforms incorporate technologies such as real-time polymerase chain reaction, isothermal nucleic acid amplification, CRISPR-based detection, microarrays, and sequencing-based methods. These systems are increasingly deployed in hospitals, emergency departments, urgent care centers, physician offices, pharmacies, ambulatory facilities, and home-care environments. Principal applications include respiratory infections, sexually transmitted infections, hospital-acquired infections, hepatitis, HIV, tuberculosis, oncology, and genetic testing.
Point-of-Care Molecular Diagnostics Market Highlights
- Assays and consumables led the product category with a 58% market share in 2025. Real-time PCR dominated the technology segment with a 45% share in 2025. Infectious disease testing accounted for 62% of market revenue in 2025. Hospitals and critical care settings represented the largest end-user segment, capturing 41% of revenue in 2025. North America led the global market with a 46% revenue share in 2025. Asia-Pacific is expected to record the fastest regional growth through 2034.
Key Point-of-Care Molecular Diagnostics Market Growth Drivers
The persistent global burden of infectious diseases remains a primary market driver. The World Health Organization estimates that 374 million new infections occur annually from four curable sexually transmitted infections, while 10.8 million people developed tuberculosis in 2023. In the United States, approximately 1.6 million chlamydia cases and more than 700,000 gonorrhea cases are reported annually. Seasonal influenza, respiratory syncytial virus, COVID-19, HIV, hepatitis, and hospital-acquired infections further increase testing requirements.
Demand for rapid molecular results is also accelerating the transition from centralized laboratories to decentralized care settings. Near-patient testing enables clinicians to diagnose infections and initiate targeted treatment during a single visit, reducing loss to follow-up and supporting more effective infection-control decisions. Rapid pathogen identification also advances antimicrobial stewardship by helping healthcare professionals avoid unnecessary empirical antibiotic use.
Regulatory and technological developments are broadening market access. CLIA-waived multiplex panels, including the BIOFIRE SPOTFIRE respiratory product range, are supporting adoption in urgent care centers, physician offices, and pharmacies. Innovations in instrument-free PCR, isothermal amplification, and CRISPR-based detection are improving portability, turnaround time, and platform accessibility. The authorization of at-home molecular tests is also creating a consumer diagnostics channel beyond conventional clinical environments.
Market Challenges
Market expansion may be moderated by the comparatively high cost of molecular cartridges, reagents, instruments, and quality-control programs. Reimbursement policies vary by geography and indication, while coverage for decentralized and home molecular testing can lag behind regulatory availability. Manufacturers must also navigate FDA clearance, CLIA-waiver requirements, and the European In Vitro Diagnostic Regulation, which may extend development timelines and increase evidence requirements.
Additional challenges include workforce training, connectivity integration, distributed quality oversight, and dependence on concentrated instrument and reagent supply chains. Variable performance outside controlled laboratory environments and uncertain consumer willingness to pay for home molecular testing may also affect adoption rates.
Product and Technology Analysis
Assays and consumables accounted for approximately 58% of point-of-care molecular diagnostics market revenue in 2025. The segment benefits from recurring demand for single-use cartridges, reagents, and test kits. Proprietary closed-cartridge ecosystems also generate repeat purchases as installed instrument bases expand. Continued assay-menu development across respiratory disease, sexual health, and syndromic testing is expected to reinforce the segment's leadership through 2034.
Real-time PCR captured approximately 45% of the market in 2025. Its position is supported by extensive clinical validation, high analytical performance, broad assay availability, and large installed bases for platforms such as Cepheid GeneXpert, Roche cobas liat, and bioMerieux BIOFIRE SPOTFIRE. Isothermal nucleic acid amplification and CRISPR-based detection are expected to gain momentum as developers introduce lower-power and more portable testing formats.
Infectious diseases represented the leading application segment with a 62% share in 2025. Respiratory infections, sexually transmitted infections, hospital-acquired infections, hepatitis, HIV, and tuberculosis generate substantial testing demand across acute-care and community settings. Oncology and genetic testing represent additional opportunities as point-of-care molecular platforms expand beyond pathogen detection.
End-User Analysis
Hospitals and critical care settings accounted for approximately 41% of market revenue in 2025. Emergency departments, intensive care units, and hospital-based testing sites require rapid results to guide isolation, admission, and treatment decisions. These facilities also have the infrastructure and testing volumes needed to operate multiple molecular platforms and syndromic panels.
Physician offices, urgent care centers, ambulatory facilities, pharmacies, and home-care settings are expected to expand rapidly as CLIA-waived and over-the-counter testing options become more widely available. This decentralization is bringing molecular diagnostics closer to patients while opening new commercial channels for manufacturers.
Regional Market Outlook
North America dominated the global point-of-care molecular diagnostics market with a 46% revenue share in 2025. Regional leadership is supported by advanced healthcare infrastructure, high testing volumes, established FDA and CLIA-waiver pathways, favorable reimbursement, and a strong concentration of molecular diagnostics manufacturers. The United States remains the principal contributor, while Canada is expanding near-patient diagnostics through public health, primary care, and remote-care programs.
Asia-Pacific is forecast to be the fastest-growing regional market through 2034. Growth is being supported by substantial infectious disease burdens, rising healthcare investment, expanding diagnostic access, and government surveillance programs across China, India, Japan, South Korea, and Australia. Domestic manufacturing and affordable regional platforms are expected to increase adoption in urban, rural, and remote settings.
Europe remains a major market, led by Germany, the United Kingdom, France, Italy, and Spain. Public health investment, antimicrobial stewardship initiatives, and syndromic testing support regional demand, although implementation of the European In Vitro Diagnostic Regulation is increasing compliance requirements. Latin America, the Middle East, and Africa also present long-term opportunities due to the burden of tuberculosis, HIV, and other infectious diseases, combined with limited centralized laboratory capacity in many areas.
Competitive Landscape
The point-of-care molecular diagnostics market is consolidated, with leading companies competing through proprietary platforms, closed-cartridge systems, expanded assay menus, global distribution networks, and connectivity solutions. Manufacturing scale for cartridges and reagents remains an important competitive advantage, while emerging developers are targeting instrument-free testing, home diagnostics, and cost-sensitive markets.
Major companies operating in the market include:
- Danaher Corporation F. Hoffmann-La Roche Ltd Abbott Laboratories bioMerieux SA QIAGEN N.V. Becton, Dickinson and Company Hologic, Inc. QuidelOrtho Corporation Thermo Fisher Scientific Inc. SD Biosensor, Inc.
Specialized developers such as Visby Medical, Co-Diagnostics, and Molbio Diagnostics are also advancing portable, instrument-free, home-use, and emerging-market solutions. Strategic activity includes bioMerieux's acquisition of SpinChip Diagnostics and Roche's acquisition of LumiraDx point-of-care technology.
Recent Point-of-Care Molecular Diagnostics Market Developments
In June 2025, Danaher Corporation's Cepheid received a Health Canada medical device license for Xpert HIV-1 Viral Load XC. The extended-coverage assay is designed to monitor antiretroviral therapy effectiveness and expands the GeneXpert menu for decentralized HIV care and global health programs.
In March 2025, Visby Medical received FDA De Novo authorization for the Visby Medical Women's Sexual Health Test. The over-the-counter PCR diagnostic detects chlamydia, gonorrhea, and trichomoniasis in approximately 30 minutes, establishing a significant milestone for instrument-free molecular testing in the home.
Market Segmentation
- By product: Assays and consumables, instruments and analyzers, and software and services. By technology: Real-time PCR, isothermal nucleic acid amplification, CRISPR-based detection, microarray, sequencing-based methods, and other technologies. By application: Infectious diseases, oncology, genetic testing, and other applications. By end user: Hospitals and critical care settings, physician offices and clinics, urgent care and ambulatory centers, home care and self-testing, and other users. By geography: North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Market Outlook
The point-of-care molecular diagnostics market is positioned for sustained double-digit growth through 2034. Rising infectious disease incidence, antimicrobial resistance, decentralized healthcare delivery, expanding regulatory authorizations, and continued technology innovation are expected to increase adoption. Real-time PCR and recurring assay sales will remain central to market revenue, while CRISPR-based detection, isothermal amplification, syndromic panels, and home molecular testing create additional growth opportunities for established manufacturers and emerging developers.
Key Topics Covered:
1. Point-of-Care Molecular Diagnostics Market Report Introduction
1.1 Scope of the Study
1.2 Market Segmentation
1.3 Market Assumptions
2. Point-of-Care Molecular Diagnostics Market Executive Summary
2.1 Market at a Glance
3. Point-of-Care Molecular Diagnostics Market Key Factors Analysis
3.1 Point-of-Care Molecular Diagnostics Market Drivers
3.1.1 Rising Burden of Infectious Disease and Antimicrobial Resistance
3.1.2 Demand for Rapid, Near-Patient, Decentralized Testing
3.1.3 Expansion of CLIA-Waiver and Syndromic Multiplex Testing
3.1.4 Emergence of Home and Over-the-Counter Molecular Testing
3.2 Point-of-Care Molecular Diagnostics Market Restraints and Challenges
3.2.1 High Cost per Test and Reimbursement Variability
3.2.2 Regulatory Complexity and IVDR Transition
3.2.3 Consumer-Pay and Operational Barriers
3.3 Point-of-Care Molecular Diagnostics Market Opportunities
3.3.1 CRISPR-Based and Instrument-Free Platforms
3.3.2 Emerging-Market and Home Testing Expansion
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
5.1 United States
5.2 Europe
5.3 Japan
5.4 China
6. Point-of-Care Molecular Diagnostics Market Porter's Five Forces Analysis
6.1 Bargaining Power of Suppliers
6.2 Bargaining Power of Buyers
6.3 Threat of New Entrants
6.4 Threat of Substitutes
6.5 Competitive Rivalry
7. Point-of-Care Molecular Diagnostics Market Assessment
7.1 By Product
7.1.1 Assays and Consumables
7.1.2 Instruments and Analyzers
7.1.3 Software and Services
7.2 By Technology
7.2.1 Real-Time PCR
7.2.2 Isothermal Nucleic Acid Amplification
7.2.3 CRISPR-Based Detection
7.2.4 Microarray
7.2.5 Sequencing-Based
7.2.6 Others
7.3 By Application
7.3.1 Infectious Diseases
7.3.1.1 Respiratory Infections
7.3.1.2 Sexually Transmitted Infections
7.3.1.3 Hospital-Acquired Infections
7.3.1.4 Hepatitis and HIV
7.3.1.5 Tuberculosis
7.3.2 Oncology
7.3.3 Genetic Testing
7.3.4 Others
7.4 By End User
7.4.1 Hospitals and Critical Care Settings
7.4.2 Physician Offices and Clinics
7.4.3 Urgent Care and Ambulatory Centers
7.4.4 Home Care and Self-Testing
7.4.5 Others
7.5 By Geography
7.5.1 North America
7.5.1.1 United States Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.1.2 Canada Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.1.3 Mexico Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.2 Europe
7.5.2.1 Germany Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.2.2 United Kingdom Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.2.3 France Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.2.4 Italy Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.2.5 Spain Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.2.6 Rest of Europe Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.3 Asia-Pacific
7.5.3.1 China Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.3.2 Japan Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.3.3 India Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.3.4 Australia Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.3.5 South Korea Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.3.6 Rest of Asia-Pacific Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.4 Rest of World
7.5.4.1 Middle East Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.4.2 Africa Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
7.5.4.3 South America Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
8. Point-of-Care Molecular Diagnostics Market Competitive Landscape
8.1 Market Concentration and Structure
9. Point-of-Care Molecular Diagnostics Market Startup Funding and Investment Trends
10. Point-of-Care Molecular Diagnostics Market Company and Product Profiles
10.1 Danaher Corporation
10.1.1 Company Overview
10.1.2 Company Snapshot
10.1.3 Financial Overview
10.1.4 Product Portfolio
10.1.5 Strategic Initiatives / Entropy
10.2 F. Hoffmann-La Roche Ltd
10.2.1 Company Overview
10.2.2 Company Snapshot
10.2.3 Financial Overview
10.2.4 Product Portfolio
10.2.5 Strategic Initiatives / Entropy
10.3 Abbott Laboratories
10.3.1 Company Overview
10.3.2 Company Snapshot
10.3.3 Financial Overview
10.3.4 Product Portfolio
10.3.5 Strategic Initiatives / Entropy
10.4 bioMerieux SA
10.4.1 Company Overview
10.4.2 Company Snapshot
10.4.3 Financial Overview
10.4.4 Product Portfolio
10.4.5 Strategic Initiatives / Entropy
10.5 QIAGEN N.V.
10.5.1 Company Overview
10.5.2 Company Snapshot
10.5.3 Financial Overview
10.5.4 Product Portfolio
10.5.5 Strategic Initiatives / Entropy
10.6 Becton, Dickinson and Company
10.6.1 Company Overview
10.6.2 Company Snapshot
10.6.3 Financial Overview
10.6.4 Product Portfolio
10.6.5 Strategic Initiatives / Entropy
10.7 Hologic, Inc.
10.7.1 Company Overview
10.7.2 Company Snapshot
10.7.3 Financial Overview
10.7.4 Product Portfolio
10.7.5 Strategic Initiatives / Entropy
10.8 QuidelOrtho Corporation
10.8.1 Company Overview
10.8.2 Company Snapshot
10.8.3 Financial Overview
10.8.4 Product Portfolio
10.8.5 Strategic Initiatives / Entropy
10.9 Thermo Fisher Scientific Inc.
10.9.1 Company Overview
10.9.2 Company Snapshot
10.9.3 Financial Overview
10.9.4 Product Portfolio
10.9.5 Strategic Initiatives / Entropy
10.10 SD Biosensor, Inc.
10.10.1 Company Overview
10.10.2 Company Snapshot
10.10.3 Financial Overview
10.10.4 Product Portfolio
10.10.5 Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
A selection of companies mentioned in this report includes, but is not limited to:
- Danaher Corporation F. Hoffmann-La Roche Ltd Abbott Laboratories bioMerieux SA QIAGEN N.V. Becton, Dickinson and Company Hologic, Inc. QuidelOrtho Corporation Thermo Fisher Scientific Inc. SD Biosensor, Inc.
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment